C-Reactive Protein Monitoring and Clinical Presentation of Fever as Predictive Factors of Prolonged Febrile Neutropenia and Blood Culture Positivity after Autologous Hematopoietic Stem Cell Transplantation-Single-Center Real-Life Experience.

C-reactive protein autologous stem cell transplantation blood culture positivity febrile neutropenia

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
09 Jan 2022
Historique:
received: 07 12 2021
revised: 29 12 2021
accepted: 05 01 2022
entrez: 21 1 2022
pubmed: 22 1 2022
medline: 22 1 2022
Statut: epublish

Résumé

Febrile neutropenia (FN) is a medical emergency that requires urgent evaluation, timely administration of empiric broad-spectrum antibiotics and careful monitoring in order to optimize the patient's outcome, especially in the setting of both allogeneic and autologous hematopoietic stem cell transplant (ASCT). In this real-life retrospective study, a total of 49 consecutive episodes of FN were evaluated in 40 adult patients affected by either multiple myeloma (thirty-eight) or lymphoma (eleven), following ASCT, with nine patients having fever in both of the tandem transplantations. Febrile neutropenia occurred a median of 7 days from ASCT. Median duration of FN was 2 days, with 25% of population that had fever for at least four days. Ten patients had at least one fever spike superior to 39 °C, while the median number of daily fever spikes was two. Twenty patients had positive blood cultures with XDR germs, namely In our study, clinical characteristics of fever along with peak CRP levels were associated with a higher probability of both prolonged fever duration and positive blood culture, needing extended antibiotic therapy.

Sections du résumé

BACKGROUND BACKGROUND
Febrile neutropenia (FN) is a medical emergency that requires urgent evaluation, timely administration of empiric broad-spectrum antibiotics and careful monitoring in order to optimize the patient's outcome, especially in the setting of both allogeneic and autologous hematopoietic stem cell transplant (ASCT).
METHODS METHODS
In this real-life retrospective study, a total of 49 consecutive episodes of FN were evaluated in 40 adult patients affected by either multiple myeloma (thirty-eight) or lymphoma (eleven), following ASCT, with nine patients having fever in both of the tandem transplantations.
RESULTS RESULTS
Febrile neutropenia occurred a median of 7 days from ASCT. Median duration of FN was 2 days, with 25% of population that had fever for at least four days. Ten patients had at least one fever spike superior to 39 °C, while the median number of daily fever spikes was two. Twenty patients had positive blood cultures with XDR germs, namely
CONCLUSIONS CONCLUSIONS
In our study, clinical characteristics of fever along with peak CRP levels were associated with a higher probability of both prolonged fever duration and positive blood culture, needing extended antibiotic therapy.

Identifiants

pubmed: 35054007
pii: jcm11020312
doi: 10.3390/jcm11020312
pmc: PMC8780345
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Crit Care. 2018 Oct 5;22(1):252
pubmed: 30290826
Bone Marrow Transplant. 2020 Aug;55(8):1588-1594
pubmed: 32047286
Expert Rev Anti Infect Ther. 2014 Aug;12(8):1003-16
pubmed: 24834465
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Front Med (Lausanne). 2021 May 28;8:607952
pubmed: 34124082
Cureus. 2018 Jul 8;10(7):e2945
pubmed: 30202676
Clin Infect Dis. 2011 Feb 15;52(4):e56-93
pubmed: 21258094
BMC Infect Dis. 2007 Nov 22;7:137
pubmed: 18034890
Curr Opin Infect Dis. 2014 Apr;27(2):200-10
pubmed: 24573013
Antimicrob Agents Chemother. 2014 Jul;58(7):3799-803
pubmed: 24752269
Crit Care. 2019 Aug 5;23(1):271
pubmed: 31383023
Intensive Care Med. 2020 Mar;46(3):383-400
pubmed: 31965266
Crit Care Med. 2019 Nov;47(11):1485-1492
pubmed: 31389839
Ann Hematol. 2020 Aug;99(8):1917-1924
pubmed: 32556455
Haematologica. 2015 Sep;100(9):e373-6
pubmed: 25862702
Braz J Microbiol. 2015 Mar 04;45(4):1415-21
pubmed: 25763049
Infection. 2014 Feb;42(1):5-13
pubmed: 23975584
Hematology Am Soc Hematol Educ Program. 2013;2013:414-22
pubmed: 24319213
Ann Hematol. 2003 Oct;82 Suppl 2:S105-17
pubmed: 13680173
Haematologica. 2013 Dec;98(12):1836-47
pubmed: 24323984
Infect Chemother. 2021 Mar;53(1):63-74
pubmed: 33538132
J Clin Oncol. 2015 Oct 1;33(28):3199-212
pubmed: 26169616
Eur J Clin Microbiol Infect Dis. 2013 Jul;32(7):841-50
pubmed: 23354675

Auteurs

Daniela Carcò (D)

Unità Operativa di Laboratorio Analisi Chimco Cliniche, Mediterranean Institute of Oncology, Via Penninazzo 7, 95029 Viagrande, Italy.

Uros Markovic (U)

Unità Operativa di Oncoematologia e BMT Unit, Mediterranean Institute of Oncology, Via Penninazzo 7, 95029 Viagrande, Italy.
Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98122 Messina, Italy.

Paolo Castorina (P)

Unità Operativa di Laboratorio Analisi Chimco Cliniche, Mediterranean Institute of Oncology, Via Penninazzo 7, 95029 Viagrande, Italy.
Dipartimento di Fisica, Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy.
Faculty of Mathematics and Physics, Charles University, V Holešovičkach 2, 18000 Prague, Czech Republic.
Dipartimento di Fisica e Astronomia, Università di Catania, 95123 Catania, Italy.

Valeria Iachelli (V)

Unità Operativa di Laboratorio Analisi Chimco Cliniche, Mediterranean Institute of Oncology, Via Penninazzo 7, 95029 Viagrande, Italy.

Tecla Pace (T)

Unità Operativa di Laboratorio Analisi Chimco Cliniche, Mediterranean Institute of Oncology, Via Penninazzo 7, 95029 Viagrande, Italy.

Paola Guardo (P)

Unità Operativa di Laboratorio Analisi Chimco Cliniche, Mediterranean Institute of Oncology, Via Penninazzo 7, 95029 Viagrande, Italy.

Gabriella Amato (G)

Unità Operativa di Oncoematologia e BMT Unit, Mediterranean Institute of Oncology, Via Penninazzo 7, 95029 Viagrande, Italy.

Federica Galbo (F)

Unità Operativa di Oncoematologia e BMT Unit, Mediterranean Institute of Oncology, Via Penninazzo 7, 95029 Viagrande, Italy.

Paola Scirè (P)

Unità Operativa di Oncoematologia e BMT Unit, Mediterranean Institute of Oncology, Via Penninazzo 7, 95029 Viagrande, Italy.

Gaetano Moschetti (G)

Unità Operativa di Oncoematologia e BMT Unit, Mediterranean Institute of Oncology, Via Penninazzo 7, 95029 Viagrande, Italy.

Classifications MeSH